Parkinson disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• TNF 0
• APOE 1
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• JAK 0
• STAT3 0
• TREM2 0
• HDAC 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

24 of 31+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · I01

  Peripheral orexin agonists to improve motor function in a mouse model of Parkinson’s Disease

  Minneapolis Va Medical Center· Minneapolis, United States· until Sept 2030

• U.S. Department of Veterans Affairs · I01

  Clinical and Neuropathological Characterization of Parkinsonism Related to TBI in Veterans (CANPARK-TBI)

  James J Peters Va Medical Center· Bronx, United States· until Sept 2030

• NIH NEI · R01

  Retinal Cell Loss in Diabetic Retinopathy

  Wayne State University· Detroit, United States· US$387,500 awarded in fiscal year 2026· until May 2030

• NIH NIDDK · F31

  Skeletal muscle MIRO1 Mediates Insulin Resistance and Muscular Complications in Type 2 Diabetes

  University of Oklahoma Hlth Sciences Ctr· Oklahoma City, United States· US$50,114 awarded in fiscal year 2026· until Sept 2028

• NIH NCI · F31

  Deciphering RNA Zipcodes: A Novel Framework for Subcellular Localization Element Annotation

  Baylor College of Medicine· Houston, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Multimodal AI-based Clinical prOgnostic Models for PArkinson's Symptoms progression and Subtyping (mAIcompass)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €435,842· until Nov 2030· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Multi-scAle high-order neTwork modelling in the stUdy of human aging: A data-dRiven perspectIve using Topology and geometrY (MATURITY)

  Institut National de Recherche En Informatique Et Automatique· Le Chesnay Cedex, France· EU contribution €226,421· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  ENGINEERING NANOPARTICLE-WATER COUPLING; ionic, hypoxic, logic and molecular contrast switches (WATERGATING)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,113,066· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Single-vesicle PlAtform for Real-Time detection of membrane-catalyzed Aggregation and transmission (SPARTA)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €1,500,000· until Nov 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 1,435 running projects, newest first. Listed amounts together: US$796.5m + €184.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  High-Dose Ambroxol in GBA1-Related Parkinson

  NCT06193421· Agyany Pharma LTD· Updated 9 Nov 2026

  “Sponsor's decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

  NCT07011771· Capsida Biotherapeutics, Inc.· Updated 22 Jun 2026

  “Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Parkinson's Disease in Type 1 Gaucher Disease

  NCT07886879· Icahn School of Medicine at Mount Sinai· Source

• Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

  NCT06993142· Radboud University Medical Center· Source

• Ambroxol as a Disease-modifying Treatment in GBA-PD

  NCT05287503· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

• LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease

  NCT04668898· Icahn School of Medicine at Mount Sinai· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 76
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 35
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 103
• Magnetic Resonance Imaging 369
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 186
• Genome-Wide Association Study 83

• Single nuclear RNA sequencing shows altered microglial and astrocytic functions in post-mortem Parkinson's disease tissue.

  BMC Genom Data, Jul 2026

• Experimental and computational methods for allelic imbalance analysis from single-nucleus RNA-seq data.

  Genome Biol, Apr 2026

• M[Formula: see text]DGAT: Multi-view multi-scale dynamic graph attention network(GAT) based prediction of Parkinson's disease(PD) progression using whole-blood RNA sequencing data.

  Sci Rep, Mar 2026

• RNAseq Analysis of the Cerebellum Reveals Significant Gene Dysregulation That May Explain Chronic Disease Progression in Mild Traumatic Brain Injury.

  J Neurosci Res, Feb 2026

• Minimum Redundancy Maximum Relevance Feature Selection-Application on Single-Cell RNA Sequencing Dataset.

  Adv Exp Med Biol, Jan 2026

• Immune involvement in neuropsychiatric disorders: Insights from single-cell transcriptomic studies.

  Psychiatry Clin Neurosci, Dec 2025

• MtDNA-depleted neuronal cell transcriptomes reveal Alzheimer's disease-related changes.

  Alzheimers Dement, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.